Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Analysis Period
1.4 Market Data Reporting Unit
1.4.1 Value
1.5 Market Size Breakdown by Segment
1.5.1 Market Segmentation by Product Type
1.5.2 Market Segmentation by Cell Line Type
1.5.3 Market Segmentation by Service Type
1.5.4 Market Segmentation by Region
1.6 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.1.1 Paid
2.1.2 Unpaid
2.1.3 P&S Intelligence Database
2.2 Primary Research
2.2.1 Breakdown of Primary Research, by Region
2.2.2 Breakdown of Primary Research, by Industry Participant
2.2.3 Breakdown of Primary Research, by Designation
2.2.4 Breakdown of Primary Research, by Company Type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Currency Conversion Rates
2.6 Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Definition of Market Segments
4.1 By Product Type
4.1.1 Drug Substance
4.1.2 Drug Product
4.2 By Cell Line Type
4.2.1 Microbial
4.2.2 Mammalian
4.2.3 Viral Vector & Other Modalities
4.3 By Service Type
4.3.1 Clinical
4.3.2 Commercial
Chapter 5. Industry Outlook
5.1 Market Dynamics
5.1.1 Trends
5.1.1.1 Partnerships and mergers & acquisitions
5.1.1.2 Expansion of healthcare facilities
5.1.1.3 Shift in preference toward CDMOs
5.1.2 Drivers
5.1.2.1 Surging incidence of chronic diseases
5.1.2.2 Rising outsourcing of R&D activities
5.1.2.3 Companies involve in partnerships with biologics CDMOs to introduce novel products
5.1.2.4 Rising geriatric population
5.1.3 Impact Analysis of Drivers on Market Forecast
5.1.4 Restraints
5.1.4.1 Issue regarding intellectual property
5.1.4.2 Product recall
5.1.4.3 Stringent regulations
5.1.4.4 Unfavorable drug price control policies
5.1.5 Impact Analysis of Restraints on Market Forecast
5.1.6 Growth Opportunities and Their Impact
5.2 Impact of Covid-19
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Buyers
5.3.2 Bargaining Power of Suppliers
5.3.3 Intensity of Rivalry
5.3.4 Threat of New Entrants
5.3.5 Threat of Substitutes
Chapter 6. Global Market Size and Forecast
6.1 Overview
6.2 Market Revenue, by Product Type (2017–2030)
6.3 Market Revenue, by Cell Line Type (2017–2030)
6.4 Market Revenue, by Service Type (2017–2030)
6.5 Market Revenue, by Region (2017–2030)
Chapter 7. North America Market Size and Forecast
7.1 Overview
7.2 Market Revenue, by Product Type (2017–2030)
7.3 Market Revenue, by Cell Line Type (2017–2030)
7.4 Market Revenue, by Service Type (2017–2030)
7.5 Market Revenue, by Country (2017–2030)
Chapter 8. Europe Market Size and Forecast
8.1 Overview
8.2 Market Revenue, by Product Type (2017–2030)
8.3 Market Revenue, by Cell Line Type (2017–2030)
8.4 Market Revenue, by Service Type (2017–2030)
8.5 Market Revenue, by Country (2017–2030)
Chapter 9. APAC Market Size and Forecast
9.1 Overview
9.2 Market Revenue, by Product Type (2017–2030)
9.3 Market Revenue, by Cell Line Type (2017–2030)
9.4 Market Revenue, by Service Type (2017–2030)
9.5 Market Revenue, by Country (2017–2030)
Chapter 10. LATAM Market Size and Forecast
10.1 Overview
10.2 Market Revenue, by Product Type (2017–2030)
10.3 Market Revenue, by Cell Line Type (2017–2030)
10.4 Market Revenue, by Service Type (2017–2030)
10.5 Market Revenue, by Country (2017–2030)
Chapter 11. MEA Market Size and Forecast
11.1 Overview
11.2 Market Revenue, by Product Type (2017–2030)
11.3 Market Revenue, by Cell Line Type (2017–2030)
11.4 Market Revenue, by Service Type (2017–2030)
11.5 Market Revenue, by Country (2017–2030)
Chapter 12. Competitive Landscape
12.1 List of Major Players
12.2 Market Share Analysis of Key Players
12.3 Recent Strategic Developments of Key Players
12.3.1 Expansions
12.3.2 Partnerships & Collaborations
12.3.3 Acquisitions
Chapter 13. Company Profiles
13.1 Catalent Inc.
13.1.1 Business Overview
13.1.2 Product and Service Offerings
13.1.3 Key Financial Summary
13.2 Rentschler Biopharma SE
13.2.1 Business Overview
13.2.2 Product and Service Offerings
13.3 Emergent BioSolutions Inc.
13.3.1 Business Overview
13.3.2 Product and Service Offerings
13.3.3 Key Financial Summary
13.4 JRS PHARMA LP
13.4.1 Business Overview
13.4.2 Product and Service Offerings
13.5 Boehringer Ingelheim International GmbH
13.5.1 Business Overview
13.5.2 Product and Service Offerings
13.5.3 Key Financial Summary
13.6 WuXi Biologics (Cayman) Inc.
13.6.1 Business Overview
13.6.2 Product and Service Offerings
13.6.3 Key Financial Summary
13.7 Samsung Biologics Co. Ltd.
13.7.1 Business Overview
13.7.2 Product and Service Offerings
13.7.3 Key Financial Summary
13.8 Lonza Group Ltd.
13.8.1 Business Overview
13.8.2 Product and Service Offerings
13.8.3 Key Financial Summary
13.9 FUJIFILM Diosynth Biotechnologies U.S.A. Inc.
13.9.1 Business Overview
13.9.2 Product and Service Offerings
13.10 Binex Co. Ltd.
13.10.1 Business Overview
13.10.2 Product and Service Offerings
13.11 Novartis AG
13.11.1 Business Overview
13.11.2 Product and Service Offerings
13.11.3 Key Financial Summary
13.12 AbbVie Inc.
13.12.1 Business Overview
13.12.2 Product and Service Offerings
13.12.3 Key Financial Summary
13.13 Thermo Fisher Scientific Inc.
13.13.1 Business Overview
13.13.2 Product and Service Offerings
13.13.3 Key Financial Summary
Chapter 14. Appendix
14.1 Sources and References
14.2 Related Reports
LIST OF TABLES
TABLE 1 ANALYSIS PERIOD OF THE STUDY
TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
TABLE 4 GROWTH OPPORTUNITIES AND THEIR IMPACT
TABLE 5 MAJOR COVID-19 VACCINE DEALS SIGNED BY CDMO IN 2020
TABLE 6 GLOBAL BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2017–2022)
TABLE 7 GLOBAL BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2023–2026)
TABLE 8 GLOBAL BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2027–2030)
TABLE 9 GLOBAL BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2017–2022)
TABLE 10 GLOBAL BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2023–2026)
TABLE 11 GLOBAL BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2027–2030)
TABLE 12 GLOBAL BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2017–2022)
TABLE 13 GLOBAL BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2023–2026)
TABLE 14 GLOBAL BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2027–2030)
TABLE 15 GLOBAL BIOLOGICS CDMO MARKET REVENUE, BY REGION, $M (2017–2022)
TABLE 16 GLOBAL BIOLOGICS CDMO MARKET REVENUE, BY REGION, $M (2023–2026)
TABLE 17 GLOBAL BIOLOGICS CDMO MARKET REVENUE, BY REGION, $M (2027–2030)
TABLE 18 NORTH AMERICA BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2017–2022)
TABLE 19 NORTH AMERICA BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2023–2026)
TABLE 20 NORTH AMERICA BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2027–2030)
TABLE 21 NORTH AMERICA BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2017–2022)
TABLE 22 NORTH AMERICA BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2023–2026)
TABLE 23 NORTH AMERICA BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2027–2030)
TABLE 24 NORTH AMERICA BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2017–2022)
TABLE 25 NORTH AMERICA BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2023–2026)
TABLE 26 NORTH AMERICA BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2027–2030)
TABLE 27 NORTH AMERICA BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2017–2022)
TABLE 28 NORTH AMERICA BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2023–2026)
TABLE 29 NORTH AMERICA BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2027–2030)
TABLE 30 EUROPE BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2017–2022)
TABLE 31 EUROPE BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2023–2026)
TABLE 32 EUROPE BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2027–2030)
TABLE 33 EUROPE BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2017–2022)
TABLE 34 EUROPE BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2023–2026)
TABLE 35 EUROPE BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2027–2030)
TABLE 36 EUROPE BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2017–2022)
TABLE 37 EUROPE BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2023–2026)
TABLE 38 EUROPE BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2027–2030)
TABLE 39 EUROPE BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2017–2022)
TABLE 40 EUROPE BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2023–2026)
TABLE 41 EUROPE BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2027–2030)
TABLE 42 BIOLOGICS APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION, CHINA, 2019–2020
TABLE 43 APAC BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2017–2022)
TABLE 44 APAC BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2023–2026)
TABLE 45 APAC BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2027–2030)
TABLE 46 APAC BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2017–2022)
TABLE 47 APAC BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2023–2026)
TABLE 48 APAC BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2027–2030)
TABLE 49 APAC BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2017–2022)
TABLE 50 APAC BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2023–2026)
TABLE 51 APAC BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2027–2030)
TABLE 52 APAC BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2017–2022)
TABLE 53 APAC BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2023–2026)
TABLE 54 APAC BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2027–2030)
TABLE 55 LATAM BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2017–2022)
TABLE 56 LATAM BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2023–2026)
TABLE 57 LATAM BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2027–2030)
TABLE 58 LATAM BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2017–2022)
TABLE 59 LATAM BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2023–2026)
TABLE 60 LATAM BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2027–2030)
TABLE 61 LATAM BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2017–2022)
TABLE 62 LATAM BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2023–2026)
TABLE 63 LATAM BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2027–2030)
TABLE 64 LATAM BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2017–2022)
TABLE 65 LATAM BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2023–2026)
TABLE 66 LATAM BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2027–2030)
TABLE 67 MEA BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2017–2022)
TABLE 68 MEA BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2023–2026)
TABLE 69 MEA BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2027–2030)
TABLE 70 MEA BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2017–2022)
TABLE 71 MEA BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2023–2026)
TABLE 72 MEA BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2027–2030)
TABLE 73 MEA BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2017–2022)
TABLE 74 MEA BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2023–2026)
TABLE 75 MEA BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2027–2030)
TABLE 76 MEA BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2017–2022)
TABLE 77 MEA BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2023–2026)
TABLE 78 MEA BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2027–2030)
TABLE 79 LIST OF MAJOR PLAYERS
TABLE 80 CATALENT INC. – AT A GLANCE
TABLE 81 CATALENT INC. – KEY FINANCIAL SUMMARY
TABLE 82 RENTSCHLER BIOPHARMA SE – AT A GLANCE
TABLE 83 EMERGENT BIOSOLUTIONS INC. – AT A GLANCE
TABLE 84 EMERGENT BIOSOLUTIONS INC. – KEY FINANCIAL SUMMARY
TABLE 85 JRS PHARMA LP – AT A GLANCE
TABLE 86 BOEHRINGER INGELHEIM INTERNATIONAL GMBH – AT A GLANCE
TABLE 87 BOEHRINGER INGELHEIM INTERNATIONAL GMBH – KEY FINANCIAL SUMMARY
TABLE 88 WUXI BIOLOGICS (CAYMAN) INC. – AT A GLANCE
TABLE 89 WUXI BIOLOGICS (CAYMAN) INC. – KEY FINANCIAL SUMMARY
TABLE 90 SAMSUNG BIOLOGICS CO. LTD. – AT A GLANCE
TABLE 91 SAMSUNG BIOLOGICS CO. LTD. – KEY FINANCIAL SUMMARY
TABLE 92 LONZA GROUP LTD. – AT A GLANCE
TABLE 93 LONZA GROUP LTD. – KEY FINANCIAL SUMMARY
TABLE 94 FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A. INC. – AT A GLANCE
TABLE 95 BINEX CO. LTD. – AT A GLANCE
TABLE 96 NOVARTIS AG – AT A GLANCE
TABLE 97 NOVARTIS AG – KEY FINANCIAL SUMMARY
TABLE 98 ABBVIE INC. – AT A GLANCE
TABLE 99 ABBVIE INC. – KEY FINANCIAL SUMMARY
TABLE 100 THERMO FISHER SCIENTIFIC INC. – AT A GLANCE
TABLE 101 THERMO FISHER SCIENTIFIC INC. – KEY FINANCIAL SUMMARY
LIST OF FIGURES
FIG 1 MARKET SIZE BREAKDOWN BY SEGMENT
FIG 2 RESEARCH METHODOLOGY
FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION
FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY INDUSTRY PARTICIPANT
FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION
FIG 6 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE
FIG 7 DATA TRIANGULATION APPROACH
FIG 8 CURRENCY CONVERSION RATES FOR USD (2022)
FIG 9 GLOBAL BIOLOGICS CDMO MARKET SUMMARY
FIG 11 AGING POPULATION IN MAJOR REGIONS (2000–2050)
FIG 12 BARGAINING POWER OF BUYERS
FIG 13 BARGAINING POWER OF SUPPLIERS
FIG 14 INTENSITY OF RIVALRY
FIG 15 THREAT OF NEW ENTRANTS
FIG 16 THREAT OF SUBSTITUTES
FIG 17 GLOBAL BIOLOGICS CDMO MARKET SNAPSHOT
FIG 18 GLOBAL BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2017–2030)
FIG 19 GLOBAL BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2017–2030)
FIG 20 GLOBAL BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2017–2030)
FIG 21 MAJOR WORLDWIDE MARKETS FOR BIOLOGICS CDMO SERVICES, $M
FIG 22 NORTH AMERICA BIOLOGICS CDMO MARKET SNAPSHOT
FIG 23 NORTH AMERICA BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2017–2030)
FIG 24 NORTH AMERICA BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2017–2030)
FIG 25 NORTH AMERICA BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2017–2030)
FIG 26 NORTH AMERICA BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2017–2030)
FIG 27 EUROPE BIOLOGICS CDMO MARKET SNAPSHOT
FIG 28 EUROPE BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2017–2030)
FIG 29 EUROPE BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2017–2030)
FIG 30 EUROPE BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2017–2030)
FIG 31 EUROPE BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2017–2030)
FIG 32 APAC BIOLOGICS CDMO MARKET SNAPSHOT
FIG 33 APAC BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2017–2030)
FIG 34 APAC BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2017–2030)
FIG 35 APAC BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2017–2030)
FIG 36 APAC BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2017–2030)
FIG 37 LATAM BIOLOGICS CDMO MARKET SNAPSHOT
FIG 38 LATAM BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2017–2030)
FIG 39 LATAM BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2017–2030)
FIG 40 LATAM BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2017–2030)
FIG 41 LATAM BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2017–2030)
FIG 42 MEA BIOLOGICS CDMO MARKET SNAPSHOT
FIG 43 MEA BIOLOGICS CDMO MARKET REVENUE, BY PRODUCT TYPE, $M (2017–2030)
FIG 44 MEA BIOLOGICS CDMO MARKET REVENUE, BY CELL LINE TYPE, $M (2017–2030)
FIG 45 MEA BIOLOGICS CDMO MARKET REVENUE, BY SERVICE TYPE, $M (2017–2030)
FIG 46 MEA BIOLOGICS CDMO MARKET REVENUE, BY COUNTRY, $M (2017–2030)
FIG 47 GLOBAL BIOLOGICS CDMO MARKET SHARE OF KEY PLAYERS (2022)
FIG 48 CATALENT INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 49 EMERGENT BIOSOLUTIONS INC. – REVENUE SPLIT BY SEGMENT (2022)
FIG 50 BOEHRINGER INGELHEIM INTERNATIONAL GMBH – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2021)
FIG 51 WUXI BIOLOGICS (CAYMAN) INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 52 SAMSUNG BIOLOGICS CO. LTD. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 53 LONZA GROUP LTD. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 54 NOVARTIS AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 55 ABBVIE INC. – REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2022)
FIG 56 THERMO FISHER SCIENTIFIC INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
| ※参考情報 生物製剤CDMO（Contract Development and Manufacturing Organization）は、生物医薬品の開発および製造を専門とする外部委託サービスプロバイダーです。このような組織は、製薬会社やバイオテクノロジー企業に対して製品開発のための専門知識とリソースを提供します。生物製剤とは、主に細胞や微生物を利用して製造される医薬品であり、抗体、ワクチン、細胞療法製品、遺伝子治療製品などが含まれます。 生物製剤CDMO は、以下のような種類のサービスを提供します。まず、開発段階において、プロセス開発や製品の試験的製造を行うことがあげられます。これにより、製薬会社が商品化を目指す際の基礎データを収集し、製造プロセスの最適化を図ります。次に、製造段階では、GMP（Good Manufacturing Practice）に基づいた製品の大量生産を行います。製薬会社は、CDMOの生産能力や専門技術を利用することで、自社の研究開発活動に集中できるようになります。 生物製剤CDMO の用途は非常に多岐にわたります。例えば、バイオ医薬品の研究開発において、早期段階からの技術支援を受けることが可能です。また、商業段階においては、製品の大量生産や品質管理を行うことで、医薬品の市場投入を加速させる役割を果たします。特に、少量生産やオンデマンド生産が求められる新興市場やニッチな製品に対しても柔軟に対応することができる点が特徴です。 さらに、近年では生物製剤CDMO が重要視される理由として、製薬業界のトレンドが挙げられます。特に、個別化医療や細胞治療、再生医療などが注目を集める中で、製品の複雑さや製造工程の高度化が進んでいます。このような状況において、CDMOは持続可能な製造能力を提供し、製薬会社が迅速に市場ニーズに応じた製品を供給するためのパートナーシップを築く重要な存在となっています。 生物製剤 CDMO に関連する技術も進化しています。たとえば、細胞培養技術や遺伝子組換え技術は、生物製剤の製造プロセスにおいて非常に重要です。これにより、より高効率で安定した製造が可能になります。また、分析技術の進化により、製品の品質評価や安全性評価を迅速かつ正確に行うことができるようになっています。さらに、自動化技術やデジタル化が進むことで、製造過程の最適化やトレーサビリティの向上にも寄与しています。 生物製剤CDMO は、製薬業界における競争力を高めるための重要な要素です。製薬企業は、内部リソースを効率的に活用しつつ、専門知識や先端技術を持つ CDMO と連携することで、製品開発と市場投入のスピードを加速させることができるのです。特に、グローバル化が進む現代において、国際的な規制や市場の変化に迅速に対応するためには、柔軟で信頼性の高いパートナーシップが欠かせません。 今後も生物製剤CDMO は、医薬品開発に不可欠な存在としてその重要性を増していくことでしょう。技術革新とともに、より多様なニーズに応えるためのサービス展開が期待されます。これにより、患者に対して新しい治療法を提供するための環境が整い、医療の質の向上が図られることになります。生物製剤 CDMO の役割は今後ますます拡大し、医療の進歩に寄与していくことでしょう。 |
